A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Cancer
Interventions: DRUG: Venetoclax|DRUG: Capecitabine
Sponsor: AbbVie